389 related articles for article (PubMed ID: 17289772)
1. The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks.
Hawkyard CV; Koerner RJ
J Antimicrob Chemother; 2007 Mar; 59(3):347-58. PubMed ID: 17289772
[TBL] [Abstract][Full Text] [Related]
2. Comment on: The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks.
Deane A; Young R
J Antimicrob Chemother; 2008 Jan; 61(1):227; author reply 227-8. PubMed ID: 17981832
[No Abstract] [Full Text] [Related]
3. Prokinetic drug therapy in children: a review of current options.
Chicella MF; Batres LA; Heesters MS; Dice JE
Ann Pharmacother; 2005 Apr; 39(4):706-11. PubMed ID: 15755792
[TBL] [Abstract][Full Text] [Related]
4. Clinical use of erythromycin in children with gastrointestinal dysmotility.
Aanpreung P; Vajaradul C
J Med Assoc Thai; 2001 Jul; 84(7):1021-6. PubMed ID: 11759961
[TBL] [Abstract][Full Text] [Related]
5. Erythromycin for prokinesis: imprudent prescribing?
Dall'Antonia M; Wilks M; Coen PG; Bragman S; Millar MR
Crit Care; 2006 Feb; 10(1):112. PubMed ID: 16420656
[TBL] [Abstract][Full Text] [Related]
6. The use of tegaserod in critically ill patients with impaired gastric motility.
Banh HL; MacLean C; Topp T; Hall R
Clin Pharmacol Ther; 2005 Jun; 77(6):583-6. PubMed ID: 15961989
[TBL] [Abstract][Full Text] [Related]
7. Prokinetic agents in critical care.
Doherty WL; Winter B
Crit Care; 2003 Jun; 7(3):206-8. PubMed ID: 12793865
[TBL] [Abstract][Full Text] [Related]
8. Motility disorders in the ICU: recent therapeutic options and clinical practice.
Röhm KD; Boldt J; Piper SN
Curr Opin Clin Nutr Metab Care; 2009 Mar; 12(2):161-7. PubMed ID: 19202387
[TBL] [Abstract][Full Text] [Related]
9. [Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma].
Folwaczny C; Läritz M; Meurer M; Endres SP; König A; Schindlbeck N
Z Gastroenterol; 1997 Oct; 35(10):905-12. PubMed ID: 9432812
[TBL] [Abstract][Full Text] [Related]
10. [Promotility drugs use in critical care: indications and limits?].
Libert N; De Rudnicki S; Cirodde A; Janvier F; Leclerc T; Borne M; Brinquin L
Ann Fr Anesth Reanim; 2009 Nov; 28(11):962-75. PubMed ID: 19910155
[TBL] [Abstract][Full Text] [Related]
11. Prokinetic drugs for feed intolerance in critical illness: current and potential therapies.
Deane AM; Fraser RJ; Chapman MJ
Crit Care Resusc; 2009 Jun; 11(2):132-43. PubMed ID: 19485878
[TBL] [Abstract][Full Text] [Related]
12. Prokinetic therapy for feed intolerance in critical illness: one drug or two?
Nguyen NQ; Chapman M; Fraser RJ; Bryant LK; Burgstad C; Holloway RH
Crit Care Med; 2007 Nov; 35(11):2561-7. PubMed ID: 17828038
[TBL] [Abstract][Full Text] [Related]
13. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent.
Weber FH; Richards RD; McCallum RW
Am J Gastroenterol; 1993 Apr; 88(4):485-90. PubMed ID: 8470625
[TBL] [Abstract][Full Text] [Related]
14. Prokinetic therapy for gastroesophageal reflux disease.
Robinson M
Am Fam Physician; 1995 Sep; 52(3):957-62, 965-6. PubMed ID: 7653432
[TBL] [Abstract][Full Text] [Related]
15. Practicalities of nutrition support in the intensive care unit: the usefulness of gastric residual volume and prokinetic agents with enteral nutrition.
Ridley EJ; Davies AR
Nutrition; 2011 May; 27(5):509-12. PubMed ID: 21295944
[TBL] [Abstract][Full Text] [Related]
16. Use of prokinetics in the preterm infant.
Lam HS; Ng PC
Curr Opin Pediatr; 2011 Apr; 23(2):156-60. PubMed ID: 21178622
[TBL] [Abstract][Full Text] [Related]
17. Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance.
Nguyen NQ; Ching K; Fraser RJ; Chapman MJ; Holloway RH
Intensive Care Med; 2008 Jan; 34(1):169-73. PubMed ID: 17701160
[TBL] [Abstract][Full Text] [Related]
18. Role of prokinetic drugs for treatment of postoperative ileus in the horse.
Dart AJ; Hodgson DR
Aust Vet J; 1998 Jan; 76(1):25-31. PubMed ID: 9578763
[TBL] [Abstract][Full Text] [Related]
19. Erythromycin as a prokinetic: is the overall benefit corroborated?
Singh NK
Crit Care Med; 2007 May; 35(5):1446; author reply 1446-7. PubMed ID: 17446761
[No Abstract] [Full Text] [Related]
20. Use of oral erythromycin for the treatment of gastrointestinal dysmotility in preterm infants.
Ng PC
Neonatology; 2009; 95(2):97-104. PubMed ID: 19218823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
